Gschwend Jürgen E, Dahm Philipp, Fair William R
Department of Urology, University of Ulm, Prittwitzstrasse 43, 89075 Ulm, Germany.
Eur Urol. 2002 Apr;41(4):440-8. doi: 10.1016/s0302-2838(02)00060-x.
To directly compare disease specific and overall survival as endpoints in the outcome analysis of a large number of cystectomy patients and to define predictors for survival.
We retrospectively analyzed the records of 686 patients who underwent bilateral pelvic lymph node dissection (PLND) and radical cystectomy from 1980 to 1990 at Memorial Sloan-Kettering Cancer Center.
Disease specific survival characterized a clearly more favorable patient outcome than overall survival in the entire patient population as well as patients with organ confined (OC) and non-organ-confined disease (NOC): 10-year disease specific and overall survival rates for patients with OC disease (<or=P3a), negative nodes or NOC (>or=P3b) were 72.9% versus 49.1%, 61.7% versus 40.8% and 33.3% versus 22.8%, respectively. In node positive (N+) patients 10-year disease specific and overall survival rates were 27.7% and 20.9%, respectively. In a multivariate analysis organ confinement and nodal status were the strongest independent predictors of disease specific survival in all patient categories. However, stratification according to organ confinement and nodal status revealed additional prognostic parameters.
Organ-confined bladder cancer translates into high disease specific survival rates following radical cystectomy. Outcome is best characterized by disease-specific survival versus overall survival, which underestimates the impact of treatment in patients with favorable tumor and nodal stage. Subgroup analysis of patients with organ confinement and nodal status identified additional prognostic variables within the more favorable patient categories not apparent in the entire population. The poor prognosis of patients with NOC and/or N+ tumors emphasized the importance of future randomized trials in which such stratification variables may be of value.
在大量膀胱切除术患者的结局分析中,直接比较疾病特异性生存率和总生存率这两个终点,并确定生存的预测因素。
我们回顾性分析了1980年至1990年在纪念斯隆-凯特琳癌症中心接受双侧盆腔淋巴结清扫术(PLND)和根治性膀胱切除术的686例患者的记录。
在整个患者群体以及器官局限性(OC)和非器官局限性疾病(NOC)患者中,疾病特异性生存率比总生存率更能明确显示出更有利的患者结局:OC疾病(≤P3a)、淋巴结阴性或NOC(≥P3b)患者的10年疾病特异性生存率和总生存率分别为72.9%对49.1%、61.7%对40.8%和33.3%对22.8%。在淋巴结阳性(N+)患者中,10年疾病特异性生存率和总生存率分别为27.7%和20.9%。在多变量分析中,器官局限性和淋巴结状态是所有患者类别中疾病特异性生存的最强独立预测因素。然而,根据器官局限性和淋巴结状态进行分层显示了其他预后参数。
根治性膀胱切除术后,器官局限性膀胱癌可转化为较高的疾病特异性生存率。用疾病特异性生存率而非总生存率来描述结局最佳,总生存率会低估肿瘤和淋巴结分期良好患者的治疗效果。对器官局限性和淋巴结状态患者进行亚组分析,在更有利的患者类别中确定了整个群体中不明显的其他预后变量。NOC和/或N+肿瘤患者的预后较差,强调了未来随机试验的重要性,在这些试验中此类分层变量可能有价值。